Search results for "recurrence"

showing 10 items of 1036 documents

Adenoviral RB2/p130 gene transfer inhibits smooth muscle cell proliferation and prevents restenosis after angioplasty.

1999

Abstract —Smooth muscle cell (SMC) proliferation that results in neointima formation is implicated in the pathogenesis of atherosclerotic plaques and accounts for the high rates of restenosis that occur after percutaneous transluminal coronary angioplasty, a widespread treatment for coronary artery disease. Endothelial lesions trigger intense proliferative signals to the SMCs of the subintima, stimulating their reentry into the cell cycle from a resting G 0 state, resulting in neointima formation and vascular occlusion. Cellular proliferation is negatively controlled by growth-regulatory or tumor-suppressor genes, or both, such as the retinoblastoma gene family members ( RB/p105, p107, RB2…

NeointimaTranscriptional Activationmedicine.medical_specialtyPhysiologyadenovirus; cell cycle; gene therapy; p130; prb2; restenosisCellGenetic VectorsCell Cycle ProteinsPulmonary ArteryMuscle Smooth VascularAdenoviridaeCatheterizationPathogenesisRestenosisRecurrencemedicineAnimalsCarotid StenosisAngioplasty Balloon CoronaryGenes RetinoblastomaCells CulturedNeointimal hyperplasiaWound HealingRetinoblastoma-Like Protein p130business.industryCell growthGenetic transferCell CycleProteinsGenetic TherapyCell cyclemedicine.diseasePhosphoproteinsSurgeryE2F Transcription FactorsRatsDNA-Binding Proteinsmedicine.anatomical_structureCancer researchCardiology and Cardiovascular MedicinebusinessCarotid Artery InjuriesCarrier ProteinsTunica IntimaTranscription Factor DP1Cell DivisionRetinoblastoma-Binding Protein 1Transcription FactorsCirculation research
researchProduct

Minimally invasive interval debulking surgery in ovarian neoplasm (MISSION trial–NCT02324595): a feasibility study

2016

Background Laparoscopy has acquired an increasing role in the management of ovarian cancer. Laparoscopic cytoreduction could represent a new frontier for selected patients after neoadjuvant chemotherapy (NACT). Objective We sought to assess feasibility and early complication rate of minimally invasive (MI) interval debulking surgery (IDS) in stage III-IV epithelial ovarian cancer (EOC) patients after NACT. Study Design This is a phase II multicentric study in advanced EOC cases with clinical complete response after NACT, according to Gynecologic Cancer Intergroup and Response Evaluation Criteria In Solid Tumors criteria. Institutional review board approval was obtained and all patients sign…

Neoplasm Residualmedicine.medical_treatmentchemotherapyresidual0302 clinical medicine80 and overMedicineminimally invasive surgeryAged 80 and overOvarian Neoplasms030219 obstetrics & reproductive medicineadvanced ovarian cancerMedicine (all)Obstetrics and GynecologyCytoreduction Surgical ProceduresBowel resectionMiddle AgedDebulkinglaparoscopic cytoreductionNeoadjuvant TherapyIntestinesChemotherapy AdjuvantResponse Evaluation Criteria in Solid Tumors030220 oncology & carcinogenesisinterval debulking surgeryFemaleMedian bodyPeritoneumOmentumneoadjuvant chemotherapyAdultmedicine.medical_specialtyOvariectomyadvanced ovarian cancer; interval debulking surgery; laparoscopic cytoreduction; minimally invasive surgery; neoadjuvant chemotherapy; quality of life; Adult; Aged; Aged 80 and over; Appendectomy; Chemotherapy Adjuvant; Fallopian Tubes; Feasibility Studies; Female; Humans; Hysterectomy; Intestines; Middle Aged; Neoadjuvant Therapy; Neoplasm Recurrence Local; Neoplasm Residual; Omentum; Ovarian Neoplasms; Ovariectomy; Peritoneum; Cytoreduction Surgical Procedures; Laparoscopy; Medicine (all); Obstetrics and GynecologyHysterectomy03 medical and health sciencesadjuvantlocalAppendectomyHumansSurvival rateFallopian TubesAgedHysterectomybusiness.industryAdvanced ovarian cancer interval debulking surgery laparoscopic cytoreduction minimally invasive surgery neoadjuvant chemotherapy quality of life adult aged 80 and over appendectomy chemotherapy adjuvant fallopian tubes feasibility studies female humans hysterectomy intestines middle aged neoadjuvant therapy neoplasm recurrence local neoplasm residual omentum ovarian neoplasms ovariectomy peritoneum cytoreduction surgical procedures laparoscopyPerioperativeneoplasm recurrenceSurgerySettore MED/40 - GINECOLOGIA E OSTETRICIAquality of lifeFeasibility StudiesLaparoscopyLymphadenectomyNeoplasm Recurrence LocalbusinessneoplasmAmerican Journal of Obstetrics and Gynecology
researchProduct

Multiplicity and history have a detrimental effect on survival in patients with T1G3 bladder tumors selected for conservative treatment.

2008

Purpose: In the absence of Tis tumor we assessed whether history and multiplicity have a detrimental effect on conservative treatment in carefully selected patients with T1G3 bladder carcinoma. Materials and Methods: Between January 1976 and December 1999, 165 select patients with T1G3 bladder tumors were conservatively treated with transurethral resection plus adjuvant intravesical therapy. Patients with concomitant or previous Tis, previous T1G3, tumor size greater than 3 cm and more than 3 lesions were excluded from analysis. Repeat transurethral resection was not routinely performed. However, cytology had to be negative for atypia before the start of adjuvant intravesical therapy. Resul…

NephrologyAdultMalemedicine.medical_specialtyUrologymedicine.medical_treatmentDisease-Free SurvivalPredictive Value of TestsRisk FactorsCytologyInternal medicineCarcinomaAtypiaMedicineHumansSurvival rateAgedNeoplasm StagingAged 80 and overChemotherapyChi-Square Distributionbusiness.industryPatient Selectionbladder tumors T1G3 survival multiplicity historyMiddle Agedmedicine.diseaseSurgerySurvival RateLogistic ModelsUrinary Bladder NeoplasmsChemotherapy AdjuvantConcomitantPredictive value of testsDisease ProgressionUrologic Surgical ProceduresFemaleNeoplasm Recurrence Localbusiness
researchProduct

Oncologic outcome and continence recovery after laparoscopic radical prostatectomy: 3 years' follow-up in a "second generation center".

2006

Objectiues: Laparoscopic radical prostatectomy in major centers guarantees oncologic and functional results equal to open procedures. In our institution this operation was introduced in 2001 after an adequate training in laparoscopic surgery. We report the oncologic and functional results after 3 years of experience.Methods: We considered our first 150 patients that had undergone transperitoneal laparoscopic radical prostatectomy. The following parameters were prospectively collected and analyzed: pathological findings, surgical margins, surgical time, blood loss, hospital stay, catheterization, complications, oncologic follow-up and continence.Results: Single positive surgical margins were…

NephrologyLaparoscopic surgeryAdultMalemedicine.medical_specialtySurgical marginTime FactorsLaparoscopic radical prostatectomyTime FactorUrologymedicine.medical_treatmentBiopsyFollow-Up StudieSurgical marginRetrospective StudieInternal medicineContinencemedicineHumansLaparoscopyRetrospective StudiesAgedProstatectomyProstate cancermedicine.diagnostic_testbusiness.industryProstatectomySurgical marginsIncidenceProstatic NeoplasmsRecovery of FunctionMiddle AgedEndoscopySurgeryTreatment OutcomeUrinary IncontinenceProstate cancer; Laparoscopy; Surgical margins; ContinenceProstatic NeoplasmLaparoscopyPositive Surgical MarginNeoplasm Recurrence LocalbusinessFollow-Up StudiesHuman
researchProduct

Intravesical bleomycin in bladder tumour prophylaxis.

1986

The authors have evaluated the efficacy, tolerability and systemic absorption of bleomycin administered by intravesical route in the prophylaxis of recurrences of superficial vesical tumours after endoscopic resection (TUR). Thirty mg of bleomycin dissolved in 30 ml of saline solution were instilled in the bladder once a week for the first month and then once a month for 12 months. The instilled fluid was held in the bladder for 1 hour. The systemic absorption of the drug was evaluated by a microbiological assay of bleomycin in plasma and in the perfusion liquid recovered from the bladder. Fifteen patients were treated; most had a long history of multiple recurrent tumours despite previous …

NephrologyMalemedicine.medical_specialtyContact timeUrologymedicine.medical_treatmentBleomycinchemistry.chemical_compoundBleomycinInternal medicinemedicineIntravesical routeHumansSalineAgedCarcinoma Transitional Cellbusiness.industryMiddle AgedSurgeryTolerabilitychemistryUrinary Bladder NeoplasmsNephrologyToxicityFemaleNeoplasm Recurrence LocalbusinessPerfusionInternational urology and nephrology
researchProduct

Huge isolated port-site recurrence after laparoscopic partial nephrectomy: a case report.

2009

A 66-yr-old man with pain and swelling in the right flank was referred to our clinic for diagnosis. In 2005, the patient underwent a laparoscopic partial nephrectomy for renal cancer of the lower pole of the right kidney. A computed tomography scan revealed a 20-cm tumor in the right abdominal wall, resulting in a suspected diagnosis of port-site metastasis from the first laparoscopic operation. The patient underwent open surgery, which confirmed the diagnosis. After the operation, the patient recovered rapidly.

NephrologyMalemedicine.medical_specialtyUrologymedicine.medical_treatmentNephrectomySettore MED/24 - UrologiaMetastasisLaparoscopynephrectomy recurrenceAbdominal wallNeoplasm SeedingInternal medicinePort-site metastasismedicineHumansLaparoscopyKidney cancer; Laparoscopy; Port-site metastasisCarcinoma Renal CellAgedmedicine.diagnostic_testbusiness.industryAbdominal WallKidney cancermedicine.diseaseNephrectomyKidney NeoplasmsSurgeryEndoscopymedicine.anatomical_structureLaparoscopybusinessKidney cancerKidney diseaseEuropean urology
researchProduct

Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy

2018

PURPOSE: To evaluate the oncological impact of postponing radical cystectomy (RC) to allow further conservative therapies prior to progression in a large multicentre retrospective cohort of T1-HG/G3 patients initially treated with BCG. METHODS: According to the time of RC, the population was divided into 3 groups: patients who did not progress to muscle-invasive disease, patients who progressed before radical cystectomy and patients who experienced progression at the time of radical cystectomy. Clinical and pathological outcomes were compared across the three groups. RESULTS: Of 2451 patients, 509 (20.8%) underwent RC. Patients with tumors > 3 cm or with CIS had earlier cystectomies (HR = 1…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyKaplan-Meier EstimateSettore MED/24 - UrologiaCohort Studies0302 clinical medicineRetrospective StudieMultivariate AnalysiOutcomeeducation.field_of_studyHigh riskBladder cancerMiddle AgedPrognosisEditorialTreatment OutcomeLocal030220 oncology & carcinogenesisBCG VaccineFemaleSurvival AnalysiBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; UrologyHumanmedicine.medical_specialtyPrognosiUrologyPopulationUrologyOutcomesT1G3CystectomyRisk AssessmentDisease-Free SurvivalCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansNeoplasm InvasivenesseducationSurvival analysisProportional Hazards ModelsRetrospective StudiesAgedNeoplasm StagingNeoplasm InvasiveneCarcinoma Transitional CellBladder cancerbusiness.industryProportional hazards modelBladder cancer; Cystectomy; Extravesical disease; High risk; Outcomes; T1G3; Aged; BCG Vaccine; Carcinoma Transitional Cell; Cohort Studies; Cystectomy; Disease-Free Survival; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Multivariate Analysis; Neoplasm Invasiveness; Neoplasm Recurrence Local; Neoplasm Staging; Prognosis; Proportional Hazards Models; Retrospective Studies; Risk Assessment; Survival Analysis; Treatment Outcome; Urinary Bladder NeoplasmsCarcinomaRetrospective cohort studymedicine.diseaseSurvival AnalysisNeoplasm RecurrenceUrinary Bladder NeoplasmsConcomitantMultivariate AnalysisProportional Hazards ModelTransitional CellCohort StudieNeoplasm Recurrence LocalbusinessExtravesical disease
researchProduct

Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as pr…

2018

PURPOSE: The goals of transurethral resection of a bladder tumor (TUR) are to completely resect the lesions and to make a correct diagnosis to adequately stage and treat the patient. Persistent disease after TUR is not uncommon and is why re-TUR is recommended in T1G3 patients. When there is T1 tumor in the re-TUR specimen, very high risks of progression (82%) have been reported. We analyze the risks of recurrence, progression to muscle-invasive disease and cancer-specific mortality (CSM) according to tumor stage at re-TUR in T1G3 patients treated with BCG. METHODS: In our retrospective cohort of 2451 T1G3 patients, 934 patients (38.1%) underwent re-TUR. 667 patients had residual disease (7…

NephrologyMalemedicine.medical_treatment030232 urology & nephrologyNon-muscle invasive bladder cancer · Re-transurethral resection of the bladder · Recurrence · ProgressionSettore MED/24 - Urologia0302 clinical medicineRetrospective StudieRe-transurethral resection of the bladderRecurrenceImmunologicCause of DeathCumulative incidenceStage (cooking)Cause of deathProgressionIntravesicalAdministration IntravesicalLocal030220 oncology & carcinogenesisAdministrationBCG VaccineDisease ProgressionFemaleNon-muscle invasive bladder cancerHumanReoperationmedicine.medical_specialtyUrologyUrologyCystectomyArticleFollow-Up StudieCystectomy03 medical and health sciencesAll institutes and research themes of the Radboud University Medical CenterAdjuvants ImmunologicInternal medicineUrological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]medicineHumansAdjuvantsAgedNeoplasm StagingProportional Hazards ModelsRetrospective StudiesBladder cancerProportional hazards modelbusiness.industryNon-muscle invasive bladder cancer; Progression; Re-transurethral resection of the bladder; Recurrence; Adjuvants Immunologic; Administration Intravesical; Aged; BCG Vaccine; Cause of Death; Cystectomy; Disease Progression; Female; Follow-Up Studies; Humans; Male; Neoplasm Recurrence Local; Neoplasm Staging; Proportional Hazards Models; Reoperation; Retrospective Studies; Urinary Bladder NeoplasmsRetrospective cohort studymedicine.diseaseNeoplasm RecurrenceUrinary Bladder NeoplasmsProportional Hazards ModelNeoplasm Recurrence LocalbusinessFollow-Up Studies
researchProduct

Correlation between clinical response and urinary interleukin levels using different doses and intravesical administration schedules of interferon-al…

1993

A total of 62 patients at high risk for recurrence of superficial bladder cancer were selected for a study designed to compare the prophylactic efficacy of different doses and schedules of sequential intravesical instillations of epirubicin and interferon-alpha-2b and to evaluate which sequence could enhance the release of cytokines in the urine. Our investigations showed a significant increase in urinary concentrations of interleukins in patients who received the sequential intravesical administration of epirubicin and interferon-alpha-2b. Higher urinary concentrations of interleukins and a lower recurrence rate were detected in patients who received interferon-alpha-2b 24 h after epirubic…

Nephrologymedicine.medical_specialtyUrologyUrinary systemUrologyAlpha interferonIntravesical immunotherapyUrineInterferon alpha-2PharmacologyDrug Administration ScheduleIntravesical chemotherapyInterferon-alpha-2bSettore MED/24 - UrologiaInternal medicinemedicineHumansCombined Modality TherapyEpirubicinbusiness.industryInterleukinsInterferon-alphaInterleukinCombined Modality TherapyRecombinant ProteinsClinical trialInterleukins (urinary concentration of)Administration IntravesicalUrinary Bladder NeoplasmsInterleukin-2Interleukin-4Neoplasm Recurrence LocalbusinessInterleukin-1Epirubicinmedicine.drugUrological Research
researchProduct

Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis

2014

Background: Data on survival and safety of sorafenib for hepatocellular carcinoma recurrence after liver transplant are still equivocal. Aim: We performed a meta-analysis of published studies, with the aim of estimating the 1-year rates of survival, analysing the variability in survival rates and, finally, identifying the factors associated with a longer survival. Methods: Data from 8 of the 17 selected studies were pooled, while the other 9 were excluded because survival rates were missing. All included studies were retrospective. Results: Overall, the 1-year survival ranged from 18% to 90%. Tumour progression was the main cause of death. The second cause was bleeding, reported only in pat…

NiacinamidePhenylurea CompoundOncologySorafenibmedicine.medical_specialtyCarcinoma HepatocellularHepatocellular carcinomamedicine.medical_treatmentAntineoplastic AgentsLiver transplantationAntineoplastic AgentRecurrenceInternal medicinemedicineHumansIn patientPostoperative PeriodProspective cohort studyLiver transplantSurvival rateCause of deathHepatologybusiness.industryPhenylurea CompoundsLiver NeoplasmsGastroenterologySorafenibmedicine.diseaseLiver TransplantationSurvival RateReceptors Vascular Endothelial Growth FactorLiver NeoplasmHepatocellular carcinomaMeta-analysisNeoplasm Recurrence LocalbusinessHumanmedicine.drugDigestive and Liver Disease
researchProduct